NetworkNewsBreaks – Ideaya Biosciences, Inc. (NASDAQ: IDYA) Featured in ROTH Equity Research Report
Ideaya Biosciences, Inc. (NASDAQ: IDYA) was featured in a recent equity research report published by ROTH Capital Partners LLC. The report reads, “We are initiating coverage of Ideaya with a Buy rating and $12 PT. Ideaya is a biotech company developing a pipeline of synthetically-lethality preclinical candidates, in addition to an in-licensed PKC inhibitor (IDE196|LXS196) from Novartis (NVS-NC) for the treatment of GNAQ|GNA11 mutant solid tumors. Data from a Phase 1/2 study of IDE196 is expected during 2Q|3Q 2020, and Ideaya's first syntheticallly lethal drug candidate should enter the clinic in 2H20. Below we highlight four reasons we like the…







